Amphastar Pharmaceuticals (AMPH) Other Operating Expenses (2013 - 2026)

Amphastar Pharmaceuticals' Other Operating Expenses history runs 14 years deep, the most recent figure standing at $11.9 million for Q1 2026.

• On a quarterly basis, Other Operating Expenses fell 40.65% year-over-year to $11.9 million in Q1 2026; TTM through Mar 2026 was $81.9 million, a 6.47% increase from a year earlier, with the FY2025 full-year figure at $85.8 million, up 16.14% from the prior year.
• Other Operating Expenses declined to $11.9 million in Q1 2026 per AMPH's latest filing, from $32.0 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $32.0 million in Q4 2025 and bottomed at $5.5 million in Q4 2022.
• The 5-year median for Other Operating Expenses is $16.2 million (2022), against an average of $16.0 million.
• Biggest YoY gain for Other Operating Expenses was 273.15% in 2023; the steepest drop was 70.53% in 2023.
• Year by year, Other Operating Expenses stood at $5.5 million in 2022, then jumped by 273.15% to $20.4 million in 2023, then surged by 31.01% to $26.8 million in 2024, then advanced by 19.77% to $32.0 million in 2025, then slumped by 62.77% to $11.9 million in 2026.
• Per Business Quant, the three latest AMPH Other Operating Expenses figures stand at $11.9 million (Q1 2026), $32.0 million (Q4 2025), and $27.7 million (Q3 2025).